Related Experiment Video
Updated: Dec 7, 2025
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma
Yang Liu1, Myla S Strawderman2,3, Kwanza T Warren4
1Department of Neurosurgery, School of Medicine and Dentistry, University of Rochester, Rochester, NY, U.S.A. yang_liu@urmc.rochester.edu kevin_walter@urmc.rochester.edu.
Background/Aim:
Whether adding tumor treating fields (TTF) to the Stupp protocol increases survival for glioblastoma (GBM) patients in routine clinical care remains unknown.
Patients And Methods:
We retrospectively identified adult patients with newly diagnosed GBM (n=104) treated with the Stupp protocol or TTF at our Institution.
Results:
Thirty-six percent (37/104) of patients received TTF in conjunction with the Stupp protocol and these patients had increased 6-month (p=0.006) and 1-year (p=0.170), but not 2-year survival rates compared to the 67-patients who received Stupp alone. The improvement of survival rate at 6-month was further confirmed by a modified Poisson model (p=0.010). However, we did not observe any improvement in overall survival (OS) with a Cox model.
Conclusion:
While adding TTF to the Stupp protocol appeared to benefit patients with newly diagnosed GBM, this effect was mild and may be largely due to selection bias.
